Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects
It’s amazing what a vague top-line report on a Phase II study plus a relatively small bolt-on deal can do to a Big Pharma’s future prospects.
I’d say just ask new Sanofi CEO Paul Hudson, but you don’t have to. He’ll readily volunteer his growing enthusiasm now that he’s had a chance to settle into his leadership role. And you haven’t even been given a glimpse of what’s around the corner.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.